TY - JOUR
T1 - Cardiovascular risk changes after lipid lowering medications
T2 - Are they predictable?
AU - Sirtori, Cesare R.
AU - Calabresi, Laura
AU - Marchioli, Roberto
AU - Rubins, Hanna B.
PY - 2000/9/1
Y1 - 2000/9/1
N2 - Changes in cardiovascular risk after lipid lowering medications are generally expressed as relative risk reduction (RRR). Comparison of the eight major studies published in this last decade indicates that the RRRs ranged from a minimum (19%) for the LRC Study with cholestyramine, to maximal values of 34-37% for studies such as the HHS, 4S and AFCAPS/TexCAPS. These RRRs were barely related to the drugs' effects on major lipid parameters, e.g. LDL cholesterol. Instead, by using the absolute risk reduction (ARRs), easily calculated by subtracting the percentage end points for the drug treated from these values of the placebo group in all studies, a wide range of values was found, also adding to the series a non pharmacological study such as the Program on the Surgical Control of the Hyperlipidemias (POSCH) trial. Calculated ARRs were directly correlated to the baseline cardiovascular (CV) risk in all studies, thus allowing an easy prediction of a drug's effect in the selected population. Drugs with different mechanisms (statins, fibrates and resins) all fitted into this correlation nomogram. These findings clearly indicate that the CV effects of lipid changes, such as LDL cholesterol and triglyceride reduction or HDL rises, are in the same direction, and can be well predicted. The similar, almost identical behavior of drugs affecting LDL cholesterolemia to a different degree or not at all, indicates that novel approaches should be sought to improve risk reduction and that individual therapy should be ideally pursued, rather than a 'one drug' approach. (C) 2000 Elsevier Science Ireland Ltd.
AB - Changes in cardiovascular risk after lipid lowering medications are generally expressed as relative risk reduction (RRR). Comparison of the eight major studies published in this last decade indicates that the RRRs ranged from a minimum (19%) for the LRC Study with cholestyramine, to maximal values of 34-37% for studies such as the HHS, 4S and AFCAPS/TexCAPS. These RRRs were barely related to the drugs' effects on major lipid parameters, e.g. LDL cholesterol. Instead, by using the absolute risk reduction (ARRs), easily calculated by subtracting the percentage end points for the drug treated from these values of the placebo group in all studies, a wide range of values was found, also adding to the series a non pharmacological study such as the Program on the Surgical Control of the Hyperlipidemias (POSCH) trial. Calculated ARRs were directly correlated to the baseline cardiovascular (CV) risk in all studies, thus allowing an easy prediction of a drug's effect in the selected population. Drugs with different mechanisms (statins, fibrates and resins) all fitted into this correlation nomogram. These findings clearly indicate that the CV effects of lipid changes, such as LDL cholesterol and triglyceride reduction or HDL rises, are in the same direction, and can be well predicted. The similar, almost identical behavior of drugs affecting LDL cholesterolemia to a different degree or not at all, indicates that novel approaches should be sought to improve risk reduction and that individual therapy should be ideally pursued, rather than a 'one drug' approach. (C) 2000 Elsevier Science Ireland Ltd.
KW - Absolute risk
KW - Absolute risk reduction
KW - Cardiovascular risk
KW - Cholesterol lowering
KW - HDL raising
KW - Relative risk reduction
KW - Risk prediction
UR - http://www.scopus.com/inward/record.url?scp=0034283477&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034283477&partnerID=8YFLogxK
U2 - 10.1016/S0021-9150(00)00551-7
DO - 10.1016/S0021-9150(00)00551-7
M3 - Review article
C2 - 10996333
AN - SCOPUS:0034283477
SN - 0021-9150
VL - 152
SP - 1
EP - 8
JO - Atherosclerosis
JF - Atherosclerosis
IS - 1
ER -